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 ABSTRACT
Renal dysfunction often complicates the course 
of orthotopic liver transplant recipients and is asso-
ciated with increased morbid -mortality.
The aims of this study were to determine the 
incidence of chronic renal disease and its impact on 
patient survival.
Clinical data included age, gender and weight, 
aetiology of hepatic failure, presence of diabetes, 
hypertension, hepatitis B and C infection, renal 
dysfunction pretransplant and immunosuppression. 
Laboratory data included serum creatinine at days 
1, 7, 21, month 6, 12 and yearly. The glomerular 
filtration rate was determined by Cockcroft-Gault 
equation. We studied retrospectively from September 
1992 to March 2007 708 orthotopic liver transplant 
recipients. Mean age 44±12.6 years, 64% males, 17% 
diabetic, 18.8% hypertensive, 19.9% with hepatitis 
C and 3.8% hepatitis B. Renal dysfunction pretrans-
plant was known in 21.6%. Mean follow-up was 3.6 
years. Mean transplant survival 75% at 12 months. 
154 patients died. Univariate and multivariate 
analyses were performed and a p<0.05 was consid-
ered significant.
Acute kidney injury occurred in 33.2%. Chronic 
kidney disease stage 3 was observed in 34.3%, 
stage 4 in 6.2% and stage 5 in 5.1%. At the time of 
this study, 46.4% were on Cyclosporine A, 44.7% 
on tacrolimus and 8.9% on sirolimus.
Using multivariate analysis, renal dysfunction was 
correlated with renal dysfunction pre -orthotopic 
liver transplant (p<0.001), acute kidney injury 
(p<0.001), haemodialysis development (p<0.001), and 
inversely correlated with the use of mycophenolate 
mophetil (p<0.001); mortality was positively corre-
lated with renal dysfunction pretransplant (p=0.03), 
chronic kidney disease stage 4 (p=0.001), chronic 
kidney disease stage 5 (p<0.001) and inversely cor-
related with the use of tacrolimus (p=0.006).
In conclusion orthotopic liver transplant recipients 
are disposed to renal complications that have a 
negative impact on survival of these patients.
Key-Words:
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liver transplantation (OLT).
 INTRODUCTION
Orthotopic liver transplantation (OLT) has become 
the treatment of choice for advanced liver disease. 
Improved outcomes among solid organ transplant 
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recipients have contributed to the growth in the 
absolute number of patients with chronic kidney 
disease (CKD) in this group1, and this complication 
significantly compromises patients’ outcome2-4. The 
commonly suggested causes for CKD after liver 
transplantation include advanced age, hepatitis C 
virus, hypertension, diabetes mellitus, IgA neph-
ropathy, calcineurin inhibitors’ nephrotoxicity, inter-
stitial nephritis, pre -existing renal insufficiency and 
early postoperative acute kidney injury (AKI)4-9. CKD 
has been reported to occur in 4-80% of OLT recipi-
ents5, depending on criteria used to define CKD and 
duration of follow -up. Ojo et al.2 demonstrated that 
after 5 years posttransplantation 18% of these 
patients developed CKD stage 4, according to K/DIGO 
definition. More recently, O’Riordan et al.4 reported 
6% CKD in stage 4, but 56.7% in stage 3 and 2.3% 
in stage 5 at 10 years posttransplantation follow-up. 
We know that CKD is a well defined risk for increased 
morbidity and mortality and dialysis patients have 
an exceptionally high mortality rate. Likewise, post 
liver transplant kidney disease is an important cause 
of morbidity and mortality after OLT1,3,4,7. For pre-
venting decline in renal function, the use of effective 
alternative immunosuppressive agents without renal 
toxicity has been proposed, such as azathioprine, 
sirolimus or mycophenolate mophetil (MMF)10. Of 
note, all these studies do not involve a large number 
of OLT recipients, ranging from 14-569 patients.
Portugal has been recently considered a leader in 
terms of absolute number of OLT performed. In our 
unit, 708 OLT recipients were followed September 
1992 to March 2007. The aim of this retrospective 
study was to determine the incidence of chronic renal 
dysfunction after OLT, and to determine whether this 
complication affects the outcome of OLT patients.
 PATIENTS AND METHODS
We retrospectively studied 708 OLT recipients 
transplanted in our unit between September 1992 and 
March 2007 using the piggy back technique with 
partial cava clamping. Different immunosuppressive 
protocols have been used since 1992. Ciclosporin, 
azathioprine and prednisolone were used in the major-
ity of recipients up to 2003. Since then, 82% of the 
recipients have received an association of tacrolimus, 
MMF and prednisolone. Steroids were usually 
employed in a low dose (20 mg/day) during the first 
months, and then slowly decreased during a period 
of 12 months. Since 2001, sirolimus has been used in 
a limited number of recipients. We note that the 
Model for End stage Liver Disease (MELD) classifica-
tion was introduced in February 2002, but in Portugal 
it has only been used since 2007, and therefore we 
did not classify recipients according to this score.
We recorded the following data: age and weight 
at transplantation, gender, aetiology of hepatic fail-
ure, presence of diabetes mellitus, hypertension, 
hepatitis B and C infection, immunosuppression (ISS) 
and need for acute renal replacement therapy. Serum 
creatinine (Scr) values and glomerular filtration rate 
(GFR), determined by Cockcroft -Gault equation, were 
evaluated at different time points: pretransplanta-
tion, days 1, 7 and 21 posttransplantation, 6 months 
after transplantation and afterwards yearly.
Renal dysfunction pretransplantation (RD pre) was 
defined by GFR ≤60ml/min or Scr ≥1.5 mg/dl. AKI post-
transplantation was defined by the RIFLE criteria (a 
persistent decrease in renal function in the first 21 days 
– at least an increase of Scr x1.5 above baseline and/
or decreasing GFR in 25%). CKD was defined according 
to the K/DIGO Clinical Practice Guidelines: CKD stage 
3 if GFR 30-59 ml/min; CKD stage 4 if GFR 15-29 ml/
min and CKD stage 5 if GFR <15ml/min or dialysis11.
Univariate analysis (Spearman correlation) and 
multivariate analysis (linear regression, confidence 
interval of 95%, with forward method) were performed 
using the SPSS system 15.0 (SPSS Inc., Chicago, IL) 
and a p<0.05 was considered statistically significant.
 RESULTS
Clinical data are summarised in Table I. The mean 
follow -up was 3.6±3.4 years (ranging from 1 day to 15 
years), 28.8% (204/708 patients) had more than five 
years’ follow-up and 6.5% (46/708) were followed for 
more than 10 years. The majority of patients were male 
(64%). The most common indication for OLT in our 
population was familial amyloidotic polyneuropathy, 
Portuguese type (n=217), followed by alcoholic cirrhosis 
(n=143) and viral hepatitis cirrhosis (n=123; 27 patients 
with hepatitis B virus infection and 96 with hepatitis C 
virus – HCV infection), primary billiar cirrhosis (n=35), 
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autoimmune hepatitis (n=28), primary sclerosing cir-
rhosis (n=9) and Amanita Phalloides intoxication (n=9). 
A hepatic nodule was present in 66 patients.
Renal dysfunction prior to OLT was present in 133 
patients (21.6%) and 14 of these patients had hepa-
torenal syndrome (HRS): eight of these 14 patients 
died, with a mean follow-up of three weeks; three 
patients recovered renal function with no need for 
renal replacement therapy, and three patients 
needed dialysis temporarily, recovering renal func-
tion within 22 days after OLT.
 Acute kidney injury
AKI was registered in 33.2% (235 patients) of 
OLT. CKD developed in 70% of these recipients 
(n=164/235, r=0.3, p<0.0001) and 9% of these 
(n=21/235) are on haemodialysis due to terminal 
chronic renal failure (r=0.45, p<0.0001).
AKI was significantly more frequent in HCV 
infected patients (r=0.08, p=0.02) and less frequent 
in recipients with familial amyloidotic polyneuropa-
thy (r= -0.1, p=0.003).
AKI was a risk factor for development of CKD in 
all stages in both univariate and multivariate analy-
sis (CKD stage 3: p<0.001, 95% CI 0.2 to 0.4, stage 
4: p<0.001, 95% CI 0.2 to 0.5 and stage 5: p<0.001, 
95% CI 0.3 to 0.6).
 Chronic kidney disease
CKD was a common complication, and 323 OLT 
recipients developed variable degrees of renal fail-
ure: 34.3% (n=243) developed CKD stage 3, diag-
nosed at a mean follow -up of 11.4±17.1 months’ 
posttransplantation, 6.2% (n=44) had CKD stage 4 
at a mean follow -up of 22.3±27.7 months, and 5.1% 
(n=36) attained CKD stage 5 at a mean follow -up of 
14.1±26.3 months. Analysing the population with 
more than 5 years’ follow-up (n=204), 52% (106/204) 
developed CKD stage 3 to 5d, and 9.8% (n=20/204) 
presented CKD stage 4 or 5. If we analysed the 
population with 10 or more years’ follow-up, this 
number would reach 70%: stage 3 would be 
observed in 56.6% (n=26/46), and stage 4 or 5 in 
13% (n= 6/46).
As mentioned previously, CKD was observed in 
70% of patients who suffered from AKI. In addition, 
CKD was also present in 33.2% (157/473 recipients) 
patients without any preceding episodes of acute 
injury of the kidney, and 25.4% (n=120/473) of these 
patients developed a stage 3 and 7.9% (n=37/473) 
progressed to stage 4 or 5.
On univariate analysis, all three stages positively 
correlated between themselves (p<0.0001). Using 
Spearman’s correlations, risk factors for CKD devel-
opment were age (r=0.2; p<0.0001), female gender 
(r=0.1, p=0.006), alcoholic cirrhosis (r=0.1; p=0.01), 
primary billiar cirrhosis (r=0.07; p=0.04) and hyper-
tension (r=0.1; p=0.002). Familial amyloidotic 
polyneuropathy was inversely correlated with devel-
opment of CKD (r= -0.1; p<0.001). Each stage was 
also positively correlated with RD pre -OLT (stage 3: 
r=0.3; p<0.001; stage 4: r=0.1; p=0.001; stage 5: 
r=0.1; p=0.002), and AKI (stage 3: r=0.3; p<0.001; 
stage 4: r=0.1; p=0.01; stage 5: r=0.1; p=0.001). 
Table I
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Stages 4 and 5, the worst in terms of severity, were 
correlated with need for acute haemodialysis (stage 
4: r=0.2; p<0.0001; stage 5: r=0.7; p<0.0001) and 
with mortality (stage 4: r=0.1; p=0.04; stage 5d: 
r=0.3; p<0.001).
According to multivariate analysis (Table II), risk 
factors for CKD development were age (p=0.001, 
95% CI 0.002 to 0.007), renal dysfunction prior to 
OLT (p<0.001, 95% CI 0.4 to 0.5), AKI (p<0.001, 95% 
CI 0.2 to 0.3), and need for haemodialysis (p<0.001, 
95% CI 0.2 to 0.4). Stages 4 and 5 were posi-
tively correlated with mortality (stage 4: p=0.005, 
95% CI 0.02 to 0.1; stage 5: p<0.001, 95% CI 0.01 
to 0.02).
 Immunosuppression (ISS)
During the observation period, the majority of 
patients were treated with calcineurin inhibitor asso-
ciated to an anti-metabolite. In terms of most recent 
ISS, 46.4% of patients were on Cyclosporine A (CyA) 
associated with azathioprine (AZA) or mycophenolate 
mofetil (MMF), 44.7% were on tacrolimus mostly 
associated with MMF and 8.9% were on sirolimus. 
Sirolimus was more frequently used in recipients 
with evidence of renal dysfunction prior to OLT 
(15.8% versus 7.3% without previous renal dysfunc-
tion; p=0.0013), and in recipients with evidence of 
AKI (p=0.001).
There was no impact on CKD development when-
ever calcineurine inhibitors were or not used, prob-
ably due to the fact that almost all patients were 
under these drugs. Correlating ISS and permanent 
renal dysfunction (CKD stage 4), univariate analysis 
showed a positive correlation between the use of 
AZA (r=0.13, p=0.001), CyA (r=0.12, p=0.003) and 
sirolimus (r=0.16; p<0.001). In contrast, the use of 
tacrolimus (r= -0.12; p=0.002) and MMF (r= -0.16; 
p<0.001) were inversely correlated with the develop-
ment of CKD stage 4, suggesting a protective effect 
on renal dysfunction.
On multivariate analysis, sirolimus continued to 
show a positive correlation with the development 
of CKD stage 4 (p=0.008, 95% CI 0.05 -0.31). CKD 
stage 4 was inversely correlated with use of MMF 
(p<0.001, 95% CI -0.2 to -0.07). In multivariate 
analysis the use of AZA and tacrolimus had no 
apparent influence.
 Mortality
Mortality occurred in 154 patients and, as 
described above, and using Spearman correlation, 
was higher in patients with renal dysfunction 
(acute or chronic), particularly in CKD stage 5, 
occurring in 75% (27/36, r=0.3; p<0.0001). Others 
prognostic factors in terms of mortality were age 
(r=0.1; p=0.001), RD prior to OLT (r=0.1; p=0.001), 
HRS (r=0.09; p=0.01), need for acute dialysis 
(r=0.4; p<0.001) and ISS with AZA (r=0.1; p=0.007). 
The use of tacrolimus and MMF had a favourable 
impact (r= -0.1; p=0.006 and r=-0.9; p=0.02, 
respectively). Familial amyloidotic polyneuropathy 
was inversely correlated with mortality (r=-0.1; 
p=0.001).
Using linear regression, mortality was correlated 
with RD pre-OLT (r=0.03, 95% CI 0.006 to 0.1), CKD 
stage 4 (p=0.001, 95% CI 0.07 to 0.3), and stage 5 
(p<0.001, 95% CI 0.5 to 0.7), and was inversely 
associated with tacrolimus use (p=0.006, 95% CI -01 
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Table II





95% CI p R2
CKD development
Age 0.002 to 0.007 0.001
0.04
RD prior to OLT 0.4 to 0.5 <0.001
Acute renal failure 0.2 to 0.3 <0.001
Dialysis requirement 0.2 to 0.4 <0.001
CKD (GFR <45ml/min)
Sirolimus 0.05 to 0.31 0.008
0.004
MMF -0.2 to -0.07 <0.001
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to -0.02). We did not find any correlation between 
mortality and retransplantation.
 DISCUSSION
Renal dysfunction proved to be a common com-
plication in OLT patients and when present has a 
strong negative impact on survival. Of our 708 OLT 
patients, almost 50% developed CKD at the end of 
follow -up, defined by GFR<60 ml/min after at least 
six months’ posttransplantation. In those patients 
that were followed for a 10 year period, only 30.4% 
of surviving recipients did not have evidence of CKD. 
Risk factors for all the three stages of CKD attained 
were presence of renal dysfunction, either pretrans-
plantation or as acute injury posttransplantation.
According to our data, RD pre-OLT was observed 
in 133 patients. Reliance on Scr typically leads to an 
overestimation of renal function before OLT, par-
ticularly in those with malnutrition, low muscle mass 
and oedema1 and consequently we cannot exclude 
that the number of patients with previous renal 
dysfunction may have been underestimated. Despite 
this limitation, the presence of RD pre-OLT was a 
risk factor for occurrence of AKI, development of 
CKD and for high mortality. RD pre-OLT has been 
shown to influence postoperative morbidity and 
mortality in patients undergoing OLT12-14. Coincident 
with these findings, the MELD system created the 
MELD score, relying on bilirubin, international nor-
malised ratio and Scr, to allocate organs to waiting 
list patients. With this score, renal failure becomes 
a major factor in the decision for most urgent liver 
transplant8. After the introduction of MELD system 
no study showed an increase in post -OLT mortali-
ty14,15 and renal function remains an independent 
predictor of death following OLT14. The MELD score 
was introduced only after 2007 in Portugal and as 
our study period goes back to 1992, we did not use 
this score for patient classification.
The other important risk factor for CKD develop-
ment was AKI. The incidence of AKI ranges from 12 
to 70%16-18 depending on criteria used to define 
AKI after OLT. The aetiology of AKI is multifactorial 
and it may be precipitated by preoperative, intra-
operative and postoperative factors19. AKI predis-
poses the patients to further complications, such 
as the development of CKD or high mortality19,20. 
Our study demonstrated exactly the same.
ISS regimes have a well known impact on renal 
disease posttransplant. Although both calcineurin 
inhibitors are well known nephrotoxines6,10,23, tac-
rolimus has been associated with a better out-
come23,24, as we saw in our study. A similar obser-
vation was noted with MMF use. Some studies have 
already shown that introduction of therapy with MMF 
in OLT is beneficial in renal function, allowing reduc-
tion or withdrawal of calcineurin inhibitors10,23. Our 
data shows that, using multivariate analysis, the 
potential benefit of tacrolimus is lost and only MMF 
remains as renal protector. However this apparent 
benefit may only result from the shorter follow -up 
of patients treated with these two immunosuppres-
sants. Recent reports showed that sirolimus, associ-
ated with lower levels of calcineurin inhibitors, 
improved renal function in OLT recipients24-26. Our 
results are not in concordance with those and we 
believe that this discrepancy may be related to the 
late introduction of sirolimus in our patients, when 
they already had renal dysfunction.
Patient survival was also compromised with any 
renal impairment. In fact, this issue is severely influ-
enced by renal dysfunction, with a 40% survival at 
5 years (Kaplan Meyer) for patients that required 
any kind of dialysis. Immunosuppressant therapies 
were also implicated in patient survival.
Our study has several limitations. First of all, it is 
a retrospective study and we could not obtain all 
desirable data. Secondly, the renal function estimate 
is based on Scr, which only increases markedly when 
the GFR has decreased to less than 50% of normal. 
Kniepeiss et al.27 have suggested that cystatin C, a 
protease inhibitor, is superior to Scr or GFR as a 
prognostic marker in patients with RD after trans-
plantation27,28. Thirdly, the recipient selection was 
not based on the MELD score, as stated. Finally, the 
number of familial amyloidotic polyneuropathy 
patients is very high and not comparable to the 
majority of liver centres. Nevertheless, our familial 
amyloidotic polyneuropathy patients had less AKI 
events (p<0.005), less renal dysfunction prior to OLT 
(p=0.01) and less CKD than the other patients 
(p<0.0001). We analysed the data excluding these 
patients and the results were similar to those pre-
sented here.
Impact of renal dysfunction on liver transplantation: 
a retrospective study in 708 orthotopic liver transplant recipients
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 CONCLUSIONS
OLT recipients are disposed to acute and chronic 
renal complications. Chronic renal dysfunction 
appears as one of the main prognostic markers of 
clinical evolution in these patients.
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